Asher Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.asherbio.com
A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
Phase 1
Recruiting
- Conditions
- Non Small Cell Lung CancerMelanomaRenal Cell CarcinomaSolid TumorSquamous Cell Carcinoma of Head and Neck
- Interventions
- Biological: AB248Biological: pembrolizumab
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Asher Biotherapeutics, Inc.
- Target Recruit Count
- 462
- Registration Number
- NCT05653882
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸UCSF, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath